Parkinson’s Disease Beyond Motor Control

4

Why Parkinson’s Is More Than a Tremor

Parkinson’s disease is frequently misunderstood as a condition defined solely by tremors and rigidity. Yet up to 20% of patients experience no motor symptoms at all, according to KSL. The reality is far more complex: non-motor symptoms—such as sleep disturbances, anxiety, cognitive decline, and chronic pain—often emerge years before motor signs and can be just as debilitating. These invisible challenges turn routine tasks into monumental struggles, pushing patients toward isolation and diminished quality of life. Dr. Sunil Rathore, a neurologist at Holy Cross Hospital – Salt Lake, frames the condition as a “much larger and more complex puzzle.” The misconception that Parkinson’s is purely a motor disorder ignores the full spectrum of symptoms, including loss of smell (anosmia), REM sleep behavior disorder, and severe fatigue. For many, these non-motor effects are the most challenging aspect of living with the disease.

“Many people believe Parkinson’s is solely a motor condition, defined by tremors and rigidity. However, that’s just one piece of a much larger and more complex puzzle. The non-motor symptoms—from sleep disturbances and anxiety to cognitive changes and chronic pain—can often be the most challenging aspects for our patients.”

—Dr.

Depression: The Silent Epidemic Within Parkinson’s

Depression is one of the most underrecognized yet devastating consequences of Parkinson’s, affecting nearly half of all patients. Yale School of Medicine researchers are now exploring how synaptic plasticity—the brain’s ability to rewire itself—can be harnessed to combat this. A recent clinical trial led by Dr. Gerard Sanacora found that ketamine, a fast-acting anesthetic, produced significant antidepressant effects in Parkinson’s patients with depression compared to placebo. Results from this trial, co-led with Dr. Holmes, are expected to be published soon. The findings build on growing evidence that psychedelics like psilocybin (the active compound in “magic mushrooms”) may also restore synaptic connections in mood-related brain circuits. Yale’s open enrollment trial will use SV2A PET imaging and MRI to track whether psilocybin can reverse synaptic deficits linked to depression in Parkinson’s patients. Meanwhile, a more conventional intervention—exercise—remains the only proven method to slow disease progression while also improving mental health.

“Exercise has profound effects on mental health. Some of these effects may arise from enhancing synaptic plasticity within mood-related brain circuits identified in this study.”

—Dr.

Treatment Breakthroughs: From Levodopa to Gene Therapy

While there is no cure for Parkinson’s, advancements in treatment are offering new hope. Levodopa, a cornerstone medication for motor symptoms, continues to evolve with formulations designed to extend its effectiveness. Beyond medications, Deep Brain Stimulation (DBS) and focused ultrasound are emerging as game-changers for motor control, precisely targeting brain regions responsible for tremors and rigidity. The most promising frontier lies in disease-modifying therapies, including gene therapy and biomarker discovery. The Michael J. Fox Foundation has raised over $2.5 billion for research, accelerating the development of targeted treatments that could one day alter the course of the disease. Dr. Rebecca H. Reiser, a neurologist at Holy Cross Hospital – Jordan Valley, emphasizes the shifting landscape: “We’re seeing incredible progress in understanding Parkinson’s at a molecular level, leading to more targeted therapies and a renewed sense of hope for better symptom control—and ultimately, a cure.”

“The landscape of treatment and support is constantly evolving. We’re seeing incredible progress in understanding the disease at a molecular level, leading to more targeted therapies and a renewed sense of hope for better symptom control and ultimately, a cure. Our goal is to empower patients to live full and meaningful lives.”

—Dr. Rebecca H.

Young-Onset Parkinson’s: A Growing Challenge

Parkinson’s isn’t just a disease of the elderly. Young-Onset Parkinson’s Disease (YOPD) affects individuals under 50, with diagnoses as early as their 20s. Michael J. Fox, diagnosed at 29, became a global advocate after his own battle with the disease, significantly boosting research funding and public awareness. The invisible struggles of YOPD—such as early cognitive decline and social stigma—are often exacerbated by the misconception that the disease only strikes later in life. For younger patients, the emotional and financial toll can be devastating. Early diagnosis and proactive management are critical, yet many YOPD patients face delays in receiving proper care. Support networks, specialized exercise programs, and educational resources—such as those offered by Mountain Commonspirit—play a vital role in helping patients navigate the challenges ahead.

What Comes Next: The Road Ahead for Research and Patients

The next 12–24 months could bring pivotal developments in Parkinson’s treatment. Yale’s psychedelic trials, if successful, may redefine depression management in neurological disorders. Meanwhile, the Michael J. Fox Foundation’s push for biomarker discovery—identifying early signs of Parkinson’s before symptoms appear—could revolutionize early intervention. For patients, the message is clear: support groups, exercise, and early medical consultation remain the most effective tools available today. Yet challenges remain. The stigma around non-motor symptoms persists, and funding for research—while substantial—must continue to grow to keep pace with scientific breakthroughs. As Dr. Rathore notes, the goal isn’t just to manage symptoms but to “empower patients to live full and meaningful lives.” For now, the fight against Parkinson’s is as much about visibility as it is about science. For those affected or concerned about symptoms, consulting a neurologist remains the first step. Early diagnosis and a proactive approach can make a critical difference in quality of life.